Ivermectin Opposition Depraved – Big Pharma Ready to Market Expensive Copies of It

Ivermectin Opposition Depraved – Big Pharma Ready to Market Expensive Copies of It

Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.

Joel S. Hirschhorn

The unrelenting opposition to using ivermectin to treat and prevent COVID-19 is stronger than ever. This has resulted from a gigantic increase in demand for IVM by much of the public. Despite big media tirades against IVM, the truth about its effectiveness has reached the public through many articles on alternative news websites and truth-tellers on countless podcasts. Its success has forced Big Pharma to create expensive copies of it.

And in my book Pandemic Blunder I made the case with data that using cheap, safe, and effective generics like IVM and hydroxychloroquine would save 80% or more of COVID deaths. Esteemed physician Peter McCollough later said 85%. For the US, that means over 500,000 lives could have been saved, and globally over 4 million lives. Meanwhile, hundreds of thousands of people worldwide have died from COVID vaccines, the failed solution to the pandemic.

Merck, a maker of IVM, is getting much positive press coverage for its forthcoming prescription oral antiviral (molnupiravir). It is designed to replace IVM...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee